Silencing of Long Non-Coding RNA FGD5-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer by Regulating the miR-493-5p/DDX5 Axis

Fang Cui, MD¹, Peng Luo, PhD¹, Yao Bai, BD¹, and Jiangping Meng, PhD²

Abstract
Background: Long non-coding RNA FGD5 antisense RNA 1 (FGD5-AS1), identified to be a carcinogenic lncRNA, exhibits a regulatory role in some malignancies including non-small cell lung cancer (NSCLC). The aim of the present research is to decipher the function and underlying mechanism of FGD5-AS1 in progression of NSCLC. Methods: Expression of FGD5-AS1, miR-493-5p and DEAD-box protein 5 (DDX5) in NSCLC tissues and cells was quantified utilizing qRT-PCR. Cell proliferation was assessed by CCK-8 method. Scratch healing test and Transwell assay were used for assaying cell migration and invasion. Expressions of DDX5 and epithelial-mesenchymal transition (EMT)-related proteins were examined by Western blot. Additionally, targeting relationships between FGD5-AS1 and miR-493-5p, miR-493-5p and DDX5 were verified by dual-luciferase reporter gene assay. Results: Expression of FGD5-AS1 in NSCLC tissues and cell lines was up-regulated. Expression of FGD5-AS1 was in association with enlarged tumor size and lymph node metastasis of the patients. Knockdown of FGD5-AS1 led to the inhibition of proliferation, migration, invasion and EMT of NSCLC cells. FGD5-AS1 directly targeted miR-493-5p, while DDX5 was the target of miR-493-5p and DDX5 were verified by dual-luciferase reporter gene assay. Conclusion: FGD5-AS1 facilitates the proliferation, migration, invasion and EMT of NSCLC cells by sponging miR-493-5p and up-regulating DDX5.

Keywords
NSCLC, FGD5-AS1, miR-493-5p, DDX5

Received: September 9, 2020; Revised: November 29, 2020; Accepted: December 29, 2020.

Introduction
Lung cancer is the most common factor contributing to cancer-associated death globally.¹ Non-small cell lung cancer (NSCLC) is pathologically identified as the main subtype of lung cancer, accounting for 85% of lung cancer cases, with 5-year survival rate less than 15%.² Surgery is recommended as optimal method for early stage NSCLC, whereas the majority of patients with NSCLC reach to advanced stage by the time of diagnosis, more than 70% of whom lose optimal opportunity for surgical treatment.³ It is necessary to clarify the mechanism of NSCLC progression to identify novel therapy targets for this deadly disease.

Long non-coding RNA (lncRNA), characterized as a category of non-coding RNA whose length is more than 200 nucleotides, regulates gene expression at various levels.⁴ LncRNA is functionally in association with a series of physiological and pathological processes.⁵ Likewise, lncRNA is a participant in cancer biology. For instance, expression of lncRNA TP73-AS1 is up-regulated in NSCLC, and its high expression is predictive

¹ Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
² Assisted Reproductive Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Corresponding Author:
Jiangping Meng, Assisted Reproductive Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Email: heping737@163.com
of unfavorable prognosis; lncRNA AFAP1-AS1 promotes the migration and invasion of NSCLC cells by up-regulating of IRF7 and activating RIG-I-like receptor signaling pathway. LncRNA FGD5-AS1 has been reported to play a cancer-promoting role in colorectal cancer, oral squamous cell carcinoma, renal clear cell carcinoma and NSCLC. Nonetheless, the explicit role and underlying mechanism of FGD5-AS1 in NSCLC requires further delineation.

MicroRNA (miRNA) is short non-coding RNA composed of 19~24 nucleotides, which partially or completely binds to the 3′ untranslated region (3′UTR) of target messenger RNA (mRNA), thereupon inhibiting gene expression. MiRNA also regulates multiple physiological and pathological processes. Mounting studies have previously reported that miRNA regulates the proliferation, differentiation, migration and apoptosis of tumor cells. MiR-493-5p has been reported to exert regulatory functions in the progression of a series of cancers, including cervical cancer, hepatocellular carcinoma and NSCLC. Nonetheless, the role of miR-493-5p in NSCLC remains obscure.

DEAD box RNA helicase p68 (DEAD-box protein 5, DDX5) is a member affiliated to DEAD-box family of RNA helicases. DDX5 protein, over-expressed in multiple cancers, is reported to promote tumorigenesis and cancer progression. DDX5 is highly expressed in NSCLC, and its over-expression is associated with the detrimental prognosis of NSCLC patients.

In the present research, FGD5-AS1 was validated to be highly expressed in NSCLC tissues and cell lines. We also authenticated that silencing of FGD5-AS1 repressed the proliferation, migration, invasion and EMT of NSCLC cells, mainly via regulating miR-493-5p and DDX5 expressions.

Materials and Methods

Clinical Specimens

This work was approved by the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University. 35 cases of NSCLC samples and corresponding adjacent normal tissues were collected from Department of Thoracic Surgery, the First Affiliated Hospital of Chongqing Medical University. All tissue samples were cryopreserved in liquid nitrogen at -196 °C. All of the patients enrolled signed a written informed consent before the surgery.

Cell Culture

4 NSCLC cell lines H1650, H1299, SPC-A-1 and A549, and normal human lung epithelial cells BEAS-2B were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA) or China Center for Type Culture Collection (CCTCC, Wuhan, China). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Gibco, Grand Island, NY) and antibiotics (100 μg/mL streptomycin and 100 U/mL penicillin, Gibco, Grand Island, NY) in a humidified incubator containing 5% CO2 at 37°C.

Cell Transfection

MiR-493-5p mimic (miR-493-5p), mimic negative control (miR-NC) were obtainable from Guangzhou Ribobio Co., Ltd. (Guangzhou, China). FGD5-AS1 small interfering RNA (siRNA) (si-FGD5-AS1), negative control si-NC, pcDNA3.0-FGD5-AS1 (FGD5-AS1), and pcDNA3.0 (Vector) were purchased from GenePharma (Shanghai, China). The aforesaid plasmids or oligonucleotides were transfected into H1650 and A549 cells in logarithm phase with Lipofectamine (Invitrogen, Carlsbad, CA, USA), respectively.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

Extraction of RNA from NSCLC tissues or cells was performed utilizing TRIzol reagent (Thermo Fisher Scientific, Wilmington, DE, USA). Followed by the detection of purity and concentration with a NanoDrop2000 spectrophotometer (Thermo Fisher Scientific), 500 ng RNA was used for synthesizing cDNA with Universal cDNA Synthesis Kit (Roche, Basel, Switzerland). qRT-PCR was performed with Power SYBR Green Master Mix (Takara, Dalian, China) on ABI 7500 Real-time PCR System (Applied Biosystems, Foster City, CA, USA). The primer sequences used in this research were: FGD5-AS1 (Forward, 5′-CGTGGAGAGAATTGGGC-3′; Reverse, 5′-CGTGGAGAAGAATTGGGC-3′); DDX5 (Forward, 5′-GGCCTGATCACAGAACCATT-3′; Reverse, 5′-ACCACCTTATTCCAAAACC-3′); miR-493-5p (Forward, 5′-CTGGGCAAGCAGCTCTC-3′; Reverse, 5′-GCAGCTTCAAGGCGAAGC-3′); GAPDH (Forward, 5′-AGGACGTTGAGGTGTC-3′; Reverse, 5′-GGGTCCTCAGGGAGC-3′); and U6 (Forward, 5′-CTGGACCCGCA CAAAGAGATGTTTG-3′; Reverse, 5′-TGTGTTAACAGCGACT GTGATAGCA-3′). GAPDH and U6 were used as the endogenous controls and the relative expression levels of FGD5-AS1, miR-493-5p and DDX5 mRNA were calculated utilizing 2−ΔΔCt method.

Cell Counting Kit-8 (CCK-8) Assay

CCK-8 kit (Dojindo, Kumamoto, Japan) was utilized for detecting the proliferative ability of NSCLC cells. Briefly, H1650 and A549 cells (5 × 103 cells/well) were transferred into 96-well plates. At indicated times (12, 24, 48, 72 and 96 h), 10 μL of CCK-8 solution was added into each well. After the cells were incubated for 2 h, a microplate reader (Bio-Rad, Hercules, CA, USA) was utilized for detection of absorbance of the cells in each well at 450 nm.

Wound Healing Assays

NSCLC cells (2 × 105/well) were transferred into 12-well plates and the cells were cultured in DMEM with 10% FBS. After the cells reached 100% confluence, the monolayer cells were wounded by scraping with a 200 μL tip, and the wells were washed with serum-free medium for 3 times, and the
wound was observed and photographed. Then the cells were cultured with serum-free medium. 24 h later, the wound was observed and photographed again. Scratch healing rate = (0 h width of scratch - 24 h width of scratch)/0 h width of scratch × 100%.

**Transwell Invasion Assay**

Assessment of NSCLC cells invasiveness was completed utilizing a polycarbonate membrane Boyden chamber system (Corning, NY, USA). Upper compartment precoated with Matrigel was added with 5 × 10⁵ transfected cells in 200 μL of FBS-free medium, and the lower compartment was supplemented with DMEM containing 20% FBS. Followed by incubation for 48 h, the cells attached to lower surface of the membrane were fixed with formaldehyde, stained with crystal violet solution, photographed and counted under a microscope.

**Xenograft Model**

Animal experiments were approved by the Experimental Animal Care Commission of the First Affiliated Hospital of Chongqing Medical University. Female BALB/c nude mice (4-6 weeks old) were purchased from Topbiotech Biotechnology Co., Ltd. (Shenzhen, China). For lung metastasis model, nude mice were injected with A549 cells transfected with si-NC or si-FGD5-AS1-2 (1 × 10⁷ cells / mouse) cells via the tail vein (n = 10 in each group). After 2 weeks, all of the mice of were killed under anesthesia. Ultimately, the lung metastasis was evaluated with hematoxylin-eosin (HE) staining by a pathologist.

**Western Blot**

After the extraction of total proteins from NSCLC cells with RIPA lysis buffer (Beyotime, Shanghai, China), sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed, and then the protein was transferred onto PVDF membranes (Millipore, Billerica, MA, USA). The membranes were blocked by 5% defatted milk for 2 h at room temperature and then incubated with primary antibodies including anti-E-cadherin (1:1000; ab40772, Abcam, Shanghai, China), N-cadherin (1:1000; ab76057, Abcam), Snail (1:1000; ab216347, Abcam), Twist1 (1:1000; ab187008, Abcam), ZEB1 (1:1000; ab203829, Abcam), Vimentin (1:1000; ab92547, Abcam), DDX5 (1:1000; ab126730, Abcam) and GAPDH (1:1000; ab181602, Abcam) at 4°C for 12 h. Subsequently, the membranes were incubated with HRP-labeled secondary antibody (1:2000; Beyotime, Shanghai, China) at room temperature for 2 h. Electrochemiluminescence kit (Promega, Madison, WI, USA) was used to develop the protein bands.

**Dual-Luciferase Reporter Assay**

The fragment of FGD5-AS1 or DDX5 3’UTR containing target site for miR-493-5p was inserted into pmirGLO Dual-luciferase MiRNA Target Expression Vector (Promega, Madison, WI, USA), then FGD5-AS1-wild-type (FGD5-AS1-WT) and DDX5-wild-type (DDX5-WT) reporter vectors were established. FGD5-AS1-mutated-type (FGD5-AS1-MUT) and DDX5-mutated-type (DDX5-MUT) reporter vectors containing mutated binding sites were also constructed. Co-transfection of WT reporter or MUT reporter and miR-493-5p mimics or control miRNAs was accomplished utilizing Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA). 48 h later, Dual Luciferase Assay Kit (Promega, Madison, WI, USA) was used to examine the firefly luciferase activity, and renilla luciferase activity was employed as the control.

**RNA Pull-Down Assay**

Biotin-labeled miR-NC and biotin-labeled miR-493-5p were synthesized by Guangzhou RiboBio Co., Ltd. (Guangzhou, China). 48 h after transfection with biotin-labeled miR-NC or biotin-labeled miR-493-5p, the cells were collected to conduct an RNA pull-down experiment using Pierce™ Magnetic RNA Protein Pull-down Kit (Thermo Fisher Scientific, Wilmington, DE, USA) following the manufacturer’s instruction. Relative enrichment of FGD5-AS1 was determined using qRT-PCR from the pull-down samples.

**Statistical Analysis**

All data in this study were presented as the mean ± standard deviation, from at least 3 independent experiments. All statistical analyses were performed with SPSS 20.0 statistical software (IBM Corp., Armonk, NY, USA) with Student’s t-test or one-way ANOVA. P value less than 0.05 was deemed to be statistically significant.

**Results**

**Expression Characteristics of FGD5-AS1 in NSCLC and Its Correlation With Clinicopathological Parameters**

First of all, the expression level of FGD5-AS1 in NSCLC tissues was quantified with qRT-PCR, the findings of which indicated that FGD5-AS1 expression was remarkably up-regulated in NSCLC tissues than in adjacent normal tissues (Figure 1A). Similarly, FGD5-AS1 expression in NSCLC cell lines was up-regulated by comparison with that in normal lung epithelial cell line BEAS-2B (Figure 1B). Additionally, high expression of FGD5-AS1 in NSCLC samples was in association with enlarged tumor size and positive lymph node metastasis (Figures 1C and D). Additionally, we used the Kaplan-Meier curve and log-rank test to analyze the correlation between FGD5-AS1 expression and prognosis of NSCLC patients. The results implied that the overall survival time of NSCLC patients with high expression of FGD5-AS1 was significantly shorter than that of patients with low expression of FGD5-AS1 (Figure 1E).
Silencing of FGD5-AS1 Suppressed the Proliferation, Migration, Invasion and Epithelial-Mesenchymal Transition (EMT) of NSCLC Cells

For clarifying the function of FGD5-AS1 on regulating the malignant biological behaviors of NSCLC cells, si-NC or si-FGD5-AS1 was transiently transfected into H1650 and A549 cells. qRT-PCR implicated that expression of FGD5-AS1 in si-FGD5-AS1 group was significantly lower than that in si-NC group (Figure 2A). Successively, CCK-8, scratch healing and Transwell assays were performed for the detection of proliferation, migration and invasion of NSCLC cells, which suggested that, compared with the control group, FGD5-AS1 knockdown markedly attenuated the proliferation, migration and invasion of both H1650 and A549 cells (Figure 2B-F). Furthermore, Western blot was conducted for assessment of EMT-related proteins, which showed that silencing of FGD5-AS1 remarkably induced the expression of E-cadherin protein and

**Figure 1.** Expression of FGD5-AS1 was up-regulated in NSCLC tissues and cells. A. qRT-PCR was employed for quantifying the expression of FGD5-AS1 in NSCLC tissues and adjacent normal tissues. B. Expression of FGD5-AS1 in BEAS-2B cells and NSCLC cells (H1650, SPC-A-1, H1299 and A549) was detected by qRT-PCR. C and D. The expression of FGD5-AS1 in NSCLC patients with different tumor size (C) and different lymph node status (D) was detected by qRT-PCR. Log-rank test was used to analyze the correlation between the expression of FGD5-AS1 and the prognosis of NSCLC patients (n = 18 in high FGD5-AS1 expression group; n = 17 in low FGD5 expression group). *P < 0.05, ***P < 0.001.
Figure 2. Knockdown of FGD5-AS1 repressed the proliferation, migration, invasion and EMT of NSCLC cells. A. qRT-PCR was employed for detecting the expression of FGD5-AS1 in H1650 and A549 cells after transfection of siRNA. B. CCK-8 method was used for detecting NSCLC cell proliferation after FGD5-AS1 was silenced. C and D. Scratch healing assay was employed for examining NSCLC cell migration after FGD5-AS1 was silenced. E and F. Invasion of NSCLC cells was examined with Transwell assay after FGD5-AS1 was silenced. G and H. Western blot was used for quantifying the expressions of E-cadherin, N-cadherin, Snail, Twist1, ZEB1 and Vimentin proteins in NSCLC cells after transfection. *P < 0.05, **P < 0.01, ***P < 0.001.
repressed the expression of N-cadherin, Snail, Twist1, ZEB1 and Vimentin protein (Figure 2G and H). To further investigate the effect of FGD5-AS1 on NSCLC progression in vivo, A549 cells with FGD5-AS1 knockdown and the control cells were transplanted into the lateral caudal vein of nude mice, respectively. After 2 weeks, the mice were killed and lung metastases were examined by HE stain. As shown, the number and size of tumor nodules in the lung tissues in si-FGD5-AS1-2 group were decreased significantly compared with si-NC group (Supplementary Figure 1). Altogether, these findings indicated that inhibiting FGD5-AS1 inhibited the proliferation, migration, invasion and EMT process of NSCLC cells.

**FGD5-AS1 Regulated miR-493-5p by Serving as a Competitive Endogenous RNA (ceRNA)**

Three potential binding sites existed between FGD5-AS1 and miR-493-5p, as predicted by StarBase database (Figure 3A). Then we performed dual-luciferase reporter gene experiment to validate the prediction. As shown, miR-493-5p mimics were capable of reducing the luciferase activity of FGD5-AS1-WT, FGD5-AS1-MUT1, FGD5-AS1-MUT2 and FGD5-AS1-MUT3 groups, whereas miR-493-5p could not reduce the luciferase activity of FGD5-AS1-MUT1&2&3 groups (Figure 3B). In addition, RNA pull-down assay indicated endogenous FGD5-AS1 was enriched specifically in Bio-miR-493-5p group compared with Bio-NC group in NSCLC cells, further suggesting that miR-493-5p was a direct target of FGD5-AS1 (Figure 3C). The results of qRT-PCR showed that expression of FGD5-AS1 was markedly up-regulated in NSCLC transfected with FGD5-AS1 overexpression group (Figure 3D). As shown, silencing of FGD5-AS1 augmented the expression of miR-493-5p in NSCLC cells; while overexpression of FGD5-AS1 markedly attenuated the expression of miR-493-5p (Figure 3E). Additionally, down-regulation of miR-493-5p, and a negative correlation between FGD5-AS1 expression and miR-493-5p expression, were observed in NSCLC samples (Figure 3F and G). Collectively, these data suggested that FGD5-AS1 sponged and negatively regulated miR-493-5p in NSCLC cells.

**FGD5-AS1 Abolished the Inhibitory Effects of miR-493-5p on NSCLC Cells**

For exploring whether FGD5-AS1 was a participant in progression of NSCLC through sponging miR-493-5p, miR-493-5p mimics and FGD5-AS1 overexpression plasmid were co-transfected into H1650 and A549 cells. In contrast to miR-NC group, expression of miR-493-5p in miR-493-5p group was markedly up-regulated; conversely, by comparison with miR-493-5p group, expression of miR-493-5p in miR-493-5p+FGD5-AS1 group was reduced remarkably (Figure 4A). Compared with the miR-NC group, miR-493-5p mimics impeded the proliferation, migration and invasion of H1650 and A549 cells; while by comparison with miR-493-5p group, over-expression of FGD5-AS1 partly abrogated the inhibitory effects of miR-493-5p mimics on cell proliferation, migration and invasion (Figure 4B-D). Additionally, up-regulation of miR-186-5p remarkably elevated the expression of E-cadherin and repressed the expression of N-cadherin, Snail, Twist1, ZEB1 and Vimentin; while overexpression of FGD5-AS1 weakened the inhibitory effect of miR-493-5p mimics on EMT process (Figure 4E and F).

**FGD5-AS1 Participated in the Progression of NSCLC by Regulating miR-493-5p/DDX5 Axis**

Prediction from TargetScan database implied that miR-493-5p might bind to DDX5 3'UTR (Figure 5A). Dual-luciferase reporter gene assay manifested that miR-493-5p mimics remarkably attenuated the luciferase activity of DDX5-WT reporter, whereas the luciferase activity of DDX5-MUT reporter was not markedly affected by miR-493-5p mimics (Figure 5B and C). What’s more, in NSCLC cells, expressions of DDX5 mRNA and protein in miR-493-5p overexpression group were remarkably lower than that in miR-NC group (Figure 5D and E). These data suggested that DDX5 was a target gene of miR-493-5p. Additionally, down-regulation of DDX5 mRNA and protein expression was noted in NSCLC cells with FGD5-AS1 silenced, meanwhile, a marked augmentation of DDX5 mRNA and protein expression was observed in NSCLC cells with FGD5-AS1 overexpression (Figure 5F and G). As opposed to adjacent normal tissues, expression of DDX5 mRNA in NSCLC tissues was significantly elevated (Figure 5H). Notably, DDX5 mRNA expression was in a negative correlation with miR-493-5p expression and in a positive correlation with FGD5-AS1 expression in NSCLC tissues (Figure 5I and J). In addition, we used qRT-PCR and Western blot to detect the expressions of DDX5 mRNA and protein in H1650 and A549 cells transfected with miR-493-5p mimics or co-transfected with FGD5-AS1 overexpression plasmid. It was found that the inhibitory effect of transfection of miR-493-5p mimics on DDX5 mRNA and protein could be reversed by the overexpression of FGD5-AS1 (Figure 5K and L). It was concluded that DDX5 was the target of miR-493-5p in NSCLC cells, and expression of DDX5 was positively regulated by FGD5-AS1 indirectly.

**Discussion**

Reportedly, lncRNA is implicated in regulating various biological processes, including cell proliferation, differentiation, autophagy, apoptosis and so on. In the realm of cancer research, it has been reported that dysfunctional lncRNA exhibits a crucial role in carcinogenesis and development of cancer by regulating cell proliferation, apoptosis and metastasis. It is reported that FGD5-AS1 is highly expressed in colorectal cancer, and FGD5-AS1 knockdown contributes to the suppression of cancer cell proliferation, migration, invasion but an inducement for apoptosis. What’s more, high expression of FGD5-AS1 is associated with adverse clinicopathological parameters and short overall survival time of esophageal squamous cell carcinoma. Similarly, overexpression of FGD5-
Figure 3. MiR-493-5p was the target of FGD5-AS1 in NSCLC cells. A. Bioinformatics analysis was utilized for the prediction of binding site between FGD5-AS1 and miR-493-5p. B. Binding relationship between miR-493-5p and FGD5-AS1 was detected by dual-luciferase reporter gene assay. C. RNA pull-down assay was used to examine the interaction of FGD5-AS1 and miR-493-5p in H1650 and A549 cells. D. Expression of FGD5-AS1 in NSCLC cells transfected with FGD5-AS1 overexpression plasmid was quantified deploying qRT-PCR. E. qRT-PCR was performed for detecting the expression of miR-493-5p in NSCLC tissues and adjacent normal tissues. F. The correlation between FGD5-AS1 expression and miR-493-5p expression in NSCLC samples was analyzed. **P < 0.01, ***P < 0.001.
AS1 enhances the proliferation of NSCLC cells. Consistent with these researches, in the present work, FGD5-AS1 was experimentally proved to exhibit a cancer-promoting role in NSCLC: FGD5-AS1 expression was up-regulated in NSCLC tissues and cells, and its high expression in NSCLC tissues was associated with unfavorable pathological indexes; additionally, FGD5-AS1 knockdown impeded the proliferation, migration, invasion and EMT of NSCLC cells.

MiRNAs function predominantly in cancer biology by modulating the expressions of genes at post-transcriptional level, and they regulate almost all the malignant biological behaviors of cancer cells, including sustaining growth, distant metastasis, angiogenesis and drug resistance. A lot of miRNAs have been identified as crucial modulators in NSCLC progression, such as miR-590-5p, miR-200a-3p, miR-421. It is reported that miR-493-5p plays an important role in the development of human cancers. Specifically, miR-493-5p suppresses the proliferation and metastasis of osteosarcoma cells by targeting KLF5; overexpression of miR-493-5p facilitates the apoptosis of liver cancer cells and constrains

Figure 4. FGD5-AS1 attenuated the inhibitory effects of miR-493-5p on the malignant phenotypes of NSCLC cellsA. Expression of miR-493-5p in NSCLC cells transfected with miR-493-5p mimics or co-transfected with FGD5-AS1 overexpression plasmid was detected by qRT-PCR. B-D. CCK-8 assay (B), scratch healing assay (C) and Transwell assays (D) were employed for detecting proliferation, migration and invasion of the transfected cells. E and F. Western blot was used for quantifying the expressions of E-cadherin, N-cadherin, Snail, Twist1, ZEB1 and Vimentin protein in transfected cells. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. 

Technology in Cancer Research & Treatment
Figure 5. Expression of DDX5 was regulated by miR-493-5p and FGD5-AS1. A. Bioinformatics analysis was utilized for predicting the binding sequences on the 3'UTR of DDX5 for miR-493-5p. B and C. Binding relationship between miR-493-5p and DDX5 was detected by dual-luciferase reporter gene experiment. D and E. Expression of DDX5 mRNA and protein in miR-493-5p overexpressed NSCLC cells was quantified employing qRT-PCR and Western blot. F and G. Expression of DDX5 mRNA and protein in FGD5-AS1 knockdown or overexpression NSCLC cells was detected by qRT-PCR and Western blot. H. Expression of DDX5 mRNA in NSCLC tissues and adjacent normal tissues was assessed by qRT-PCR. I and J. The correlations between DDX5 expression and miR-493-5p expression, between DDX5 expression and FGD5-AS1 expression in NSCLC samples. K and L. The expressions of DDX5 mRNA and protein in H1650 and A549 cells transfected with miR-493-5p mimics or co-transfected with miR-493-5p and FGD5-AS1 overexpression plasmid were detected by qRT-PCR and Western blot. **P < 0.01, ***P < 0.001.
Additionally, in NSCLC, it has been reported that down-regulation of miR-493-5p facilitated the progression of NSCLC by up-regulating ITGB1.38 Consistently, in the present work, we demonstrated that miR-493-5p suppressed the malignancy of NSCLC cell lines. Reportedly, IncRNAs exert their regulatory functions in biological processes by serving as miRNA sponges, also called ceRNAs. For instance, IncRNA FENDRR impedes the progression of NSCLC via sponging miR-761 and increasing TIMP2 expression26; IncRNA PTAR the expedites proliferation, migration and invasion of NSCLC cells through sponging miR-101.29 Herein, we presented a novel ceRNA regulatory network in NSCLC: FGD5-AS1 served as a molecular sponge for miR-493-5p to repress it, and indirectly up-regulated DDX5. We revealed that FGD5-AS1 was capable of negatively regulating miR-493-5p in NSCLC cells; besides, FGD5-AS1 counteracted the tumor-suppressive effects of miR-493-5p. Our results suggested that FGD5-AS1 exerted its tumor-promoting function, at least partly, via repressing miR-493-5p.

DDX5, affiliated to DEAD (Asp-Glu-Ala-Asp) box protein family, is a highly conserved ATP-dependent RNA helicase, which is involved in RNA synthesis, splicing and transport.30,31 DDX5 protein mainly regulates growth and differentiation of cells.32 DDX5 is also highly expressed in multiple tumors, promoting the proliferation and metastasis of tumor cells. It is reported that DDX5 is capable of accelerating the proliferation of gastric cancer cells through regulating mTOR pathway.33 In breast cancer, DDX5 can not only promote the EMT of cancer cells by regulating the expressions of cytoskeleton proteins, but also form a positive regulatory loop with β-catenin/TCF-4 axis to drive metastasis.34,35 In NSCLC, DDX5 is also an oncogene. It facilitates the progression of NSCLC by activating β-catenin signaling pathway.22 In the present study, DDX5 was identified as novel target gene of miR-493-5p, and it was positively regulated by FGD5-AS1. Our work suggested that the dysregulation of FGD5-AS1/miR-493-5p axis contributed to the dysregulation of DDX5 in NSCLC.

In aggregate, we report that FGD5-AS1 exhibits a cancer-promoting role in NSCLC. FGD5-AS1 regulates the proliferation, migration, invasion and EMT of NSCLC cells by sponging miR-493-5p and up-regulating DDX5. Our work may provide inspirations for NSCLC diagnosis and treatment.

**Acknowledgments**

As non-English native speakers, we thank Hubei Yican Health Industry Co., Ltd. for its help on improving the language quality of this manuscript and submitting the manuscript on behalf of the authors. All of the authors approved the submission of this manuscript via third party. The service fee of language editing and manuscript submission, and the open access fee are paid by the office of academic research, the First Affiliated Hospital of Chongqing Medical University.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iD**

Fang Cui https://orcid.org/0000-0002-6471-0816

**Supplemental Material**

Supplemental material for this article is available online.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin*. 2019;69(1):7-34.
2. Yang HX, Woo KM, Sima CS, et al. Long-term survival based on the surgical approach to lobectomy for clinical stage I nonsmall cell lung cancer: comparison of robotic, video-assisted thoracic surgery, and thoracotomy lobectomy. *Ann Surg*. 2017;265(2):431-437.
3. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. *World J Clin Oncol*. 2017;8(1):1-20.
4. Fitzgerald KA, Caffrey DR. Long noncoding RNAs in innate and adaptive immunity. *Curr Opin Immunol*. 2014;26:140-146.
5. Jiang N, Meng X, Mi H, et al. Circulating IncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. *Clin Chim Acta*. 2018;486:26-33.
6. Zhu D, Zhou J, Liu Y, Du L, Zheng Z, Qian X. IncRNA TP73-AS1 is upregulated in non-small cell lung cancer and predicts poor survival. *Gene*. 2019;710:98-102.
7. Tang XD, Zhang DD, Jia L, Ji W, Zhao YS. IncRNA AFAP1-AS1 promotes migration and invasion of non-small cell lung cancer via up-regulating IRF7 and the RIG-I-Like receptor signaling pathway. *Cell Physiol Biochem*. 2018;50(1):179-195.
8. Li D, Jiang X, Zhang X, Cao G, Wang D, Chen Z. Long noncoding RNA FGD5-AS1 promotes colorectal cancer cell proliferation, migration, and invasion through upregulating CDC47 via sponging miR-302e. *In Vitro Cell Dev Biol Anim*. 2019;55(8):577-585.
9. Liu L, Zhan Y, Huang Y, Huang L. IncRNA FGD5-AS1 can be predicted as therapeutic target in oral cancer. *J Oral Pathol Med*. 2020;49(3):242-252.
10. Zhu H, Lu J, Zhao H, et al. Functional long noncoding RNAs (lncRNAs) in clear cell kidney carcinoma revealed by...
reconstruction and comprehensive analysis of the LncRNS-MiRNA-MRNA regulatory network. *Med Sci Monit.* 2018;24:8250-8263.

11. Fan Y, Li H, Yu Z, et al. Long non-coding RNA FGD5-AS1 promotes non-small cell lung cancer cell proliferation through sponging hsa-miR-107 to up-regulate FGFR1. *Biosci Rep.* 2020;40(1):BSR20193309.

12. Subramaniam S, Jeet V, Clements JA, Gunter JH, Batra J. Emergence of microRNAs as key players in cancer cell metabolism. *Clin Chem.* 2019;65(9):1090-1101.

13. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet.* 2004;5(7):522-531.

14. Khandelwal A, Seam RK, Gupta M, et al. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer. *Cancer Sci.* 2020;111(3):826-839.

15. Tan T, Xu XH, Lu XH, Wang XW. MiRNA-200a-3p suppresses the proliferation, migration and invasion of non-small cell lung cancer through targeting IRS2. *Eur Rev Med Pharmacol Sci.* 2020;24(2):712-720.

16. Wu F, Zhou D, Cui Y, Shen G, Li Y, Wei F. Long non-coding RNA UCA1 modulates the glycolysis of cervical cancer cells by miR-493-5p/HK2. *Int J Clin Exp Pathol.* 2018;11(8):3943-3951.

17. Gailhouste L, Liew LC, Yasukawa K, et al. MEG3-derived miR-493-5p overcomes the oncogenic feature of IGFB2-miR-483 loss of imprinting in hepatic cancer cells. *Cell Death Dis.* 2019;10(8):553.

18. Liang Z, Kong R, He Z, et al. High expression of miR-493-5p positively correlates with clinical prognosis of non small cell lung cancer by targeting oncogene ITGB1. *Oncotarget.* 2017;8(29):47389-47399.

19. Shimizu T, Inoue K, Hachiya H, Shibuya N, Shimoda M, Kubota K. Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. *J Gastroenterol.* 2014;49(9):1324-1332.

20. Abdelhaleem M. Do human RNA helicases have a role in cancer? *Biochim Biophys Acta.* 2004;1704(1):37-46.

21. Mazurek A, Luo W, Krasnitz A, Hicks J, Powers RS, Stillman B. DDX5 regulates DNA replication and is required for cell proliferation in a subset of breast cancer cells. *Cancer Discov.* 2012;2(9):812-825.

22. Wang Z, Luo Z, Zhou L, Li X, Jiang T, Fu E. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway. *Cancer Sci.* 2015;106(10):1303-1312.

23. Esteller M. Non-coding RNAs in human disease. *Nat Rev Genet.* 2011;12(12):861-874.

24. Gao J, Zhang Z, Su H, Zong L, Li Y. Long noncoding RNA FG5-AS1 acts as a competing endogenous RNA on miRNA-383 to enhance the malignant characteristics of esophageal squamous cell carcinoma by increasing sp1 expression. *Cancer Manag Res.* 2020;12:2265-2278.

25. Li X, Chen SH, Zeng JW. miR-421 is overexpressed and promotes cell proliferation in non-small cell lung cancer. *Med Princ Pract.* 2020;29(1):80-89. doi:10.1159/000503020

26. Zhang Z, Luo G, Yu C, Yu G, Jiang R, Shi X. MicroRNA-493-5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel-like factor 5. *J Cell Physiol.* 2019;234(8):13525-13533.

27. Wang G, Fang X, Han M, Wang X, Huang Q. MicroRNA-493-5p promotes apoptosis and suppresses proliferation and invasion in liver cancer cells by targeting VAMP2. *Int J Mol Med.* 2018;41(3):1740-1748.

28. Zhang G, Wang Q, Zhang X, Ding Z, Liu R. LncRNA FENDRR promotes the progression of NSCLC via regulating miR-761/TIMP2 axis. *Biomed Pharmacother.* 2019;118:109309.

29. Yu W, Sun Z, Yang L, et al. LncRNA PTAR promotes NSCLC cell proliferation, migration and invasion by sponging microRNA-101. *Mol Med Rep.* 2019;20(5):4168-4174.

30. Fuller-Pace FV. The DEAD box proteins DDX5 (p68) and DDX17 (p72): multi-tasking transcriptional regulators. *Biochim Biophys Acta.* 2013;1829(8):756-763.

31. Fuller-Pace FV, Ali S. The DEAD box RNA helicases p68 (DDX5) and p72 (DDX17): novel transcriptional co-regulators. *Biochem Soc Trans.* 2008;36(Pt 4):609-612.

32. Jones K, Wei C, Schoser B, Meola G, Timchenko N, Timchenko L. Reduction of toxic RNAs in myotonic dystrophies type 1 and type 2 by the RNA helicase p68/DDX5. *Proc Natl Acad Sci USA.* 2015;112(26):8041-8045.

33. Du C, Li DQ, Li N, et al. DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway. *Sci Rep.* 2017;7:42876.

34. Guturi KK, Sarkar M, Bhowmik A, Das N, Ghosh MK. DEAD-box protein p68 is regulated by β-catenin/transcription factor 4 to maintain a positive feedback loop in control of breast cancer progression. *Breast Cancer Res.* 2014;16(6):496.

35. Wang D, Huang J, Hu Z. RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. *Mol Cell Proteomics.* 2012;11(2):M111.011932.